Cybin announces size and pricing of previously announced overnight marketed public offering of units

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, announced today the pricing of its previously announced overnight marketed public offering (the “offering”) of an aggregate of 24,264,706 units of the company (the “units”) at a price of us$0.34 per unit for aggregate gross proceeds of us$8,2.
CYBN Ratings Summary
CYBN Quant Ranking